Cartesian Therapeutics Inc (RNAC)
EBITDA Growth
-371.14%
TTM · Period ending:
RNAC EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-371.14%period ending
Latest reported-371.14%period ending
RNAC TTM EBITDA YoY % (-47.33% → -371.14%)
Year-over-year change
High-resolution chart · PNG
RNAC ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -371.1382% | |
| -341.653% | |
| -79.6857% | |
| 82.9379% | |
| 86.4295% | |
| 86.7544% | |
| 67.6702% | |
| -721.6659% | |
| -682.2286% | |
| -2,278.0469% | |
| -701.2945% | |
| -169.6695% | |
| -160.6446% | |
| -123.7983% | |
| 794.8978% | |
| 236.6664% | |
| 224.2796% | |
| 167.3094% | |
| 91.5523% | |
| 48.4181% | |
| 37.8842% | |
| -19.8521% | |
| -28.681% | |
| -23.4578% | |
| -18.5688% | |
| -0.5914% | |
| 17.7175% | |
| 22.1944% | |
| 14.7605% | |
| 7.8855% | |
| 0.7418% | |
| -17.2143% | |
| -30.8979% | |
| -53.1751% | |
| -85.4985% | |
| -112.584% | |
| -102.326% | |
| -68.592% | |
| -47.3341% |